{"name":"Haemonetics","slug":"haemonetics","ticker":"HAE","exchange":"NYSE","domain":"haemonetics.com","description":"Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.","hq":"Boston, MA","founded":0,"employees":"~3,023","ceo":"Chris Simon","sector":"Blood Management / Medical Devices","stockPrice":57.47,"stockChange":0.46,"stockChangePercent":0.81,"marketCap":"$2.7B","metrics":{"revenue":1334027008,"revenueGrowth":4.8,"grossMargin":59.7,"rdSpend":62722000,"netIncome":167679000,"cash":245440000,"dividendYield":0,"peRatio":15.8,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-08-03","type":"earnings","headline":"Haemonetics Reports Second Quarter 2023 Financial Results","summary":"Haemonetics reported revenue of $244.4 million and adjusted EPS of $0.45 for the second quarter of 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-05-18","type":"deal","headline":"Haemonetics Announces Agreement to Acquire Celerity, Inc.","summary":"Haemonetics has entered into an agreement to acquire Celerity, Inc., a provider of blood management software solutions.","drugName":"","sentiment":"positive"},{"date":"2022-11-14","type":"regulatory","headline":"Haemonetics Receives FDA Clearance for the NexLynx Blood Management Platform","summary":"Haemonetics has received FDA clearance for the NexLynx Blood Management Platform, a software solution designed to help healthcare providers optimize blood use.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNY2ZmUGdqSnU4N1pmVXZIMExlTHlqeW1keVBZTEhxUFNfdUJZTVI0ZnN6dm80ZlM4S3AwY0V2NENaQnhJOEFkd1J0WmRhejdlQks0Zkp3a0JYaC0xNEV0RHlIRFprQzd4RUF1SGJ6QWVJcENjb1hyOTNvXzZaeEhrdU1MQ2w4ZHlHaVZjUkd5OXF2MjA4d3N6M05LbzNSYWlSR0ZUdDhidzRDMVZubk9xYVFsU082bFBySTRRXzJXdjF1QUpkWERTWmotcUl0b3ps?oc=5","date":"2026-04-06","type":"deal","source":"The Globe and Mail","summary":"1 Value Stock on Our Buy List and 2 Facing Headwinds - The Globe and Mail","headline":"1 Value Stock on Our Buy List and 2 Facing Headwinds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQQTMtaldfR3o1QTVJVFhNZEJUbmZKdFdHeWMxdTN4THlfaUVGSS10TTNIR2d6X2QtNl9fbjFMSHR1N3JZVkFsMlc4YTJVWnppY05xWXBOX1JCWGxkdThORWhScGNfbmVtNmFWRi1YUEFPOUVoLWo1Q0s3RkR4NGc4UTR1Z1BncDhXVElvbEJCeXFzWXhja0c4V05JeUtONFRJOE13VmVxRQ?oc=5","date":"2026-04-01","type":"pipeline","source":"Yahoo Finance","summary":"Is It Time To Reassess Haemonetics (HAE) After Prolonged Share Price Weakness - Yahoo Finance","headline":"Is It Time To Reassess Haemonetics (HAE) After Prolonged Share Price Weakness","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-26","type":"pipeline","source":"simplywall.st","summary":"A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st","headline":"A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNVzZHNTdLTGx2YTM4Z0w3Y1NMRUtPV2RQcVI3OWc2VkZUMlhuNHVDZElNd3R1T2Qtb3dCWTB1dXhhTUtpRWJZMjhyT1JVN0ZFOVBTY1BOSy02dVVmeC1Ec1B3bnBnMm5QekhCWWpjLTZWTEJlVlJkVWNPX0NCVjJoM2J0WDNTMGRaWm4taFZVVFU3Zw?oc=5","date":"2026-02-17","type":"pipeline","source":"Yahoo Finance","summary":"Assessing Haemonetics (HAE) Valuation After Recent Share Price Weakness - Yahoo Finance","headline":"Assessing Haemonetics (HAE) Valuation After Recent Share Price Weakness","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOSTMzWThMQzFoZGlGdVZtNDlYOXFSazNPU2EzSlN2ZWdHOXkxeU9IalFDZjJDMkNWSVNkQUhLUGJVcWtaNkx0Vl9fZGp1RVZSR1hWYVRxbkNhMzBOamhMS3FoQjJLNm1jV3JmZE9SZ2pOZEoxLS10YkRHOGppcEZiSlNpVQ?oc=5","date":"2026-02-07","type":"pipeline","source":"Yahoo Finance","summary":"Why Haemonetics (HAE) Raised 2026 Guidance After Strong Plasma And Tech Results And What It Signals - Yahoo Finance","headline":"Why Haemonetics (HAE) Raised 2026 Guidance After Strong Plasma And Tech Results And What It Signals","sentiment":"neutral"},{"date":"2026-02-05","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOamFMZFZWemhLV0FGeENIVmJMUFJCc3BxSEVjMmdTT0xzSGRoUEIzTW9LdzdkRkdVaTRpR0pxUFRSTUNMTWYwNlo4bUFKc0cxUlJ2cmdOSFdSVk51SlBaUlhoemJ6cTJqSF9vQmVtQXVWVS1zYkFiZFVpX1gxYkZ4YnBvTDdtMVFCZEJiUS1HSjVfdw?oc=5","date":"2026-01-31","type":"pipeline","source":"Yahoo Finance","summary":"Assessing Haemonetics (HAE) Valuation After Recent Share Price Swings And Margin Expansion Story - Yahoo Finance","headline":"Assessing Haemonetics (HAE) Valuation After Recent Share Price Swings And Margin Expansion Story","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOVzllNnZ0dnlmWEdweUpXRG0xX3RIbHlrc0pXamZydF94SHpFZ0l2XzFEQ00wdUZkVUl1cmxsMmM3ZDlQeThjM3lLaENjTjY3VllfZUw2c3FVSWtVU3JmdEZ1bmZ2U2hJVDk5ZHEwZ2NKYXJhTFc0Rkg0WVBHMzBHcmlhMFhOcUJKTk1JUFViSzhTUURNVFg0ekticFBPbG84cTdzWXROd0xveEk?oc=5","date":"2026-01-09","type":"deal","source":"Stock Titan","summary":"Irish maker of dissolving vessel-closure implant sold in €185M deal - Stock Titan","headline":"Irish maker of dissolving vessel-closure implant sold in €185M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOLWt5UHFyWng4OHBSMS15cVFET2x0QnM0THJXdHNhTUF5TlJ5bVNRWFlqVWtvNDJ0eDRuTnFIS1hoUmd5ZHhKY1dtcWFpUk15a2NJdXVjV0ZFdjBwY3VsZkJnLWJkR1UwOUhPZXF2d1c0SDNsNGlJOEI0THE5cWlTUTM3OWhDTTNjSWwyWWVCRTNsbUg5TkE?oc=5","date":"2026-01-09","type":"pipeline","source":"Stock Titan","summary":"New dissolving patch seals blood vessels after heart procedures - Stock Titan","headline":"New dissolving patch seals blood vessels after heart procedures","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOWnhnanVRMzgxQ3M0WEZnX3pOU0E2YjhPdE9haUZOQjd6SzlENXV0aFA4Y3l1MkdMeEtNQ1FkSXBCLU54aTdqdE9fRUprOGs5V0FNd2VnNzdPdVUzelFYWm05MTIzWWRhYlpnMUMzS2JhNTcwSnlqeTdhdnAzMGJ5Mg?oc=5","date":"2025-11-06","type":"earnings","source":"StocksToTrade","summary":"Haemonetics Reveals Fiscal Year 2026 Earnings Date Amid New Price Target Shift - StocksToTrade","headline":"Haemonetics Reveals Fiscal Year 2026 Earnings Date Amid New Price Target Shift","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Terumo BCT","Fresenius Kabi","Grifols"],"therapeuticFocus":["Blood Management"],"financials":{"source":"sec_edgar+yahoo","revenue":910373000,"revenuePeriod":"2015-03-28","revenueHistory":[{"value":910373000,"period":"2015-03-28"},{"value":938509000,"period":"2014-03-29"},{"value":938509000,"period":"2014-03-29"},{"value":891990000,"period":"2013-03-30"},{"value":891990000,"period":"2013-03-30"}],"grossProfit":748958000,"grossProfitHistory":[{"period":"2025-03-31","value":748958000},{"period":"2024-03-31","value":691548000},{"period":"2023-03-31","value":615097000},{"period":"2022-03-31","value":505502000}],"rdSpend":62722000,"rdSpendHistory":[{"period":"2025-03-31","value":62722000},{"period":"2024-03-31","value":54435000},{"period":"2023-03-31","value":50131000},{"period":"2022-03-31","value":46801000}],"sgaSpend":436789000,"operatingIncome":201186000,"operatingIncomeHistory":[{"period":"2025-03-31","value":201186000},{"period":"2024-03-31","value":173302000},{"period":"2023-03-31","value":155651000},{"period":"2022-03-31","value":71147000}],"netIncome":167679000,"netIncomeHistory":[{"period":"2025-03-31","value":167679000},{"period":"2024-03-31","value":117558000},{"period":"2023-03-31","value":115401000},{"period":"2022-03-31","value":43375000}],"eps":3.31,"epsHistory":[{"period":"2025-03-31","value":3.31},{"period":"2024-03-31","value":2.29},{"period":"2023-03-31","value":2.24},{"period":"2022-03-31","value":0.84}],"cash":306763000,"cashHistory":[{"period":"2025-03-31","value":306763000},{"period":"2024-03-31","value":178800000},{"period":"2023-03-31","value":284466000},{"period":"2022-03-31","value":259496000}],"totalAssets":2450948000,"totalLiabilities":1630112000,"totalDebt":1224788000,"equity":820836000,"operatingCashflow":181725000,"operatingCashflowHistory":[{"period":"2025-03-31","value":181725000},{"period":"2024-03-31","value":181751000},{"period":"2023-03-31","value":273058000},{"period":"2022-03-31","value":172263000}],"capex":-39278000,"capexHistory":[{"period":"2025-03-31","value":-39278000},{"period":"2024-03-31","value":-38125000},{"period":"2023-03-31","value":-191327000},{"period":"2022-03-31","value":-96509000}],"freeCashflow":142447000,"dividendsPaid":null,"buybacks":-225000000,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":109154000,"ebit":67396000,"ebitda":94781000,"period":"2025-12-31","revenue":338967000,"epsBasic":0.956146,"netIncome":44740000,"rdExpense":14187000,"epsDiluted":0.95,"grossProfit":202386000,"operatingIncome":68112000},{"sga":101615000,"ebit":58491000,"ebitda":86746000,"period":"2025-09-30","revenue":327315000,"epsBasic":0.81286,"netIncome":38684000,"rdExpense":14872000,"epsDiluted":0.81,"grossProfit":194744000,"operatingIncome":67075000},{"sga":110719000,"ebit":53872000,"ebitda":82630000,"period":"2025-06-30","revenue":321394000,"epsBasic":0.707343,"netIncome":34031000,"rdExpense":16261000,"epsDiluted":0.7,"grossProfit":192244000,"operatingIncome":53872000},{"sga":115136000,"ebit":71335000,"ebitda":99543000,"period":"2025-03-31","revenue":330599000,"epsBasic":1.178643,"netIncome":57981000,"rdExpense":15914000,"epsDiluted":1.17,"grossProfit":193050000,"operatingIncome":50704000},{"sga":106459000,"ebit":59029000,"ebitda":88054000,"period":"2024-12-31","revenue":348542000,"epsBasic":0.75,"netIncome":37494000,"rdExpense":15829000,"epsDiluted":0.74,"grossProfit":193547000,"operatingIncome":59029000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":57.47,"previousClose":57.01,"fiftyTwoWeekHigh":87.32,"fiftyTwoWeekLow":47.32,"fiftyTwoWeekRange":"47.32 - 87.32","fiftyDayAverage":58.71,"twoHundredDayAverage":62.76,"beta":0.53,"enterpriseValue":3614370304,"forwardPE":10,"priceToBook":2.95,"priceToSales":2,"enterpriseToRevenue":2.71,"enterpriseToEbitda":9.98,"pegRatio":0.84,"ebitda":362112000,"ebitdaMargin":27.1,"freeCashflow":301372384,"operatingCashflow":293220992,"totalDebt":1224579968,"debtToEquity":153.8,"currentRatio":2.95,"returnOnAssets":6.5,"returnOnEquity":12,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":10,"targetMeanPrice":80.2,"targetHighPrice":104,"targetLowPrice":62,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.2,"institutionHeldPercent":114.8,"sharesOutstanding":46471350,"floatShares":45683641,"sharesShort":1980212,"shortRatio":3.34,"shortPercentOfFloat":4.3,"epsTrailing":3.63,"epsForward":5.77,"revenuePerShare":28.28,"bookValue":19.46,"officers":[{"age":61,"name":"Mr. Christopher A. Simon","title":"CEO, President & Director"},{"age":54,"name":"Mr. James C. D'Arecca CPA","title":"CFO, Executive VP  & Financial Officer"},{"age":52,"name":"Ms. Michelle L. Basil Esq., J.D.","title":"Executive VP, General Counsel & Secretary"},{"age":55,"name":"Mr. Roy  Galvin","title":"Executive VP & Chief Commercial Officer"},{"age":54,"name":"Mr. Frank W. Chan Ph.D.","title":"Executive VP & COO"},{"age":49,"name":"Ms. Farris Maryanne Maunsell","title":"VP, Chief Accounting Officer & Principal Accounting Officer"},{"age":null,"name":"Ms. Olga  Guyette","title":"Senior Director of Investor Relations"},{"age":null,"name":"Mr. Rajeev  Varma","title":"Senior Vice President of Strategy & Corporate Development"}],"industry":"Medical Devices","irWebsite":"http://phx.corporate-ir.net/phoenix.zhtml?c=72118&p=irol-irhome","website":"https://www.haemonetics.com","phone":"781 848 7100"}}